Shots:

• The company reported the results from the P-III portion of the P-II/III trial  to evaluate mavrilimumab (10/6mg/kg, IV) vs PBO in a ratio (1:1:1) in 582 patients with COVID-19-related ARDS
• The trial failed to meet its primary efficacy 1EPs of a proportion of patients alive and free of mechanical ventilation @29Day. Additionally, the company focuses on the Arcalyst franchise including the commercial execution in recurrent pericarditis along with the development of vixarelimab and KPL-404
• Mavrilimumab is an investigational fully human mAb that targets GM-CSFRα & is currently being evaluated in GCA. The therapy has received ODD from the US FDA for GCA in 2020

Ref: Kiniska | Image: Kiniksa